{"id":"https://openalex.org/W7125836620","doi":"https://doi.org/10.2174/0118715206402646251115102627","title":"Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress","display_name":"Signalling Pathways and Inhibitors in Triple Negative Breast Cancer: Current Progress","publication_year":2026,"publication_date":"2026-01-27","ids":{"openalex":"https://openalex.org/W7125836620","doi":"https://doi.org/10.2174/0118715206402646251115102627","pmid":"https://pubmed.ncbi.nlm.nih.gov/41588901"},"language":"en","primary_location":{"id":"doi:10.2174/0118715206402646251115102627","doi":"https://doi.org/10.2174/0118715206402646251115102627","is_oa":false,"landing_page_url":"https://doi.org/10.2174/0118715206402646251115102627","pdf_url":null,"source":{"id":"https://openalex.org/S159246083","display_name":"Anti-Cancer Agents in Medicinal Chemistry","issn_l":"1568-0118","issn":["1568-0118","1871-5206","1875-5968","1875-5992"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Agents in Medicinal Chemistry","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5007428952","display_name":"Amiya Das","orcid":"https://orcid.org/0000-0002-6659-0432","observed_orcids":["https://orcid.org/0000-0002-6659-0432"]},"institutions":[{"id":"https://openalex.org/I145286018","display_name":"SRM Institute of Science and Technology","ror":"https://ror.org/050113w36","country_code":"IN","type":"education","lineage":["https://openalex.org/I145286018"]},{"id":"https://openalex.org/I191972202","display_name":"Amity University","ror":"https://ror.org/02n9z0v62","country_code":"IN","type":"education","lineage":["https://openalex.org/I191972202"]}],"countries":["IN"],"is_corresponding":true,"raw_author_name":"Amiya Das","raw_affiliation_strings":["Amity Institute of Molecular Medicine and Stem Cell Research, Amity University Uttar Pradesh, Sector 125, Noida 201313, India","Department of Chemistry, Faculty of Engineering and Technology, SRM Institute of Science and Technology, NCR Campus,Delhi-NCR Campus, Delhi-Meerut Road, Modinagar-201204, Ghaziabad, Uttar Pradesh, India"],"raw_orcid":"https://orcid.org/0000-0002-6659-0432","affiliations":[{"raw_affiliation_string":"Amity Institute of Molecular Medicine and Stem Cell Research, Amity University Uttar Pradesh, Sector 125, Noida 201313, India","institution_ids":["https://openalex.org/I191972202"]},{"raw_affiliation_string":"Department of Chemistry, Faculty of Engineering and Technology, SRM Institute of Science and Technology, NCR Campus,Delhi-NCR Campus, Delhi-Meerut Road, Modinagar-201204, Ghaziabad, Uttar Pradesh, India","institution_ids":["https://openalex.org/I145286018"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5043957222","display_name":"Viney Lather","orcid":"https://orcid.org/0000-0002-7323-3142","observed_orcids":["https://orcid.org/0000-0002-7323-3142"]},"institutions":[{"id":"https://openalex.org/I191972202","display_name":"Amity University","ror":"https://ror.org/02n9z0v62","country_code":"IN","type":"education","lineage":["https://openalex.org/I191972202"]}],"countries":["IN"],"is_corresponding":false,"raw_author_name":"Viney Lather","raw_affiliation_strings":["Amity Institute of Pharmacy, Amity University Uttar Pradesh, Sector-125, Noida, 201313, India"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amity Institute of Pharmacy, Amity University Uttar Pradesh, Sector-125, Noida, 201313, India","institution_ids":["https://openalex.org/I191972202"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5007428952"],"corresponding_institution_ids":["https://openalex.org/I145286018","https://openalex.org/I191972202"],"apc_list":null,"apc_paid":null,"fwci":2.7231,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":{"value":0.84177849,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":96},"biblio":{"volume":"26","issue":"7","first_page":"659","last_page":"677"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.0017000000225380063,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12829","display_name":"Advanced Breast Cancer Therapies","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/triple-negative-breast-cancer","display_name":"triple-negative breast cancer","score":1.0},{"id":"https://openalex.org/keywords/signaling-pathways","display_name":"signaling pathways","score":0.8999999761581421},{"id":"https://openalex.org/keywords/pi3k-akt-mtor-pathway","display_name":"PI3K/AKT/mTOR pathway","score":0.8799999952316284},{"id":"https://openalex.org/keywords/jak-stat-signaling","display_name":"JAK/STAT signaling","score":0.9879999756813049},{"id":"https://openalex.org/keywords/wnt-beta-catenin-signaling","display_name":"Wnt/\u03b2-catenin signaling","score":0.9599999785423279},{"id":"https://openalex.org/keywords/notch-signaling","display_name":"Notch signaling","score":0.984000027179718},{"id":"https://openalex.org/keywords/mapk-erk-pathway","display_name":"MAPK/ERK pathway","score":1.0},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.7820000052452087},{"id":"https://openalex.org/keywords/pembrolizumab","display_name":"pembrolizumab","score":0.9980000257492065},{"id":"https://openalex.org/keywords/sacituzumab-govitecan","display_name":"sacituzumab govitecan","score":0.9139999747276306},{"id":"https://openalex.org/keywords/antibody-drug-conjugates","display_name":"antibody-drug conjugates","score":0.9980000257492065},{"id":"https://openalex.org/keywords/small-molecule-inhibitors","display_name":"small molecule inhibitors","score":0.8859999775886536},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.847000002861023},{"id":"https://openalex.org/keywords/treatment-resistance","display_name":"treatment resistance","score":0.7749999761581421},{"id":"https://openalex.org/keywords/predictive-biomarkers","display_name":"predictive biomarkers","score":0.8230000138282776},{"id":"https://openalex.org/keywords/personalized-treatment","display_name":"personalized treatment","score":0.5509999990463257}],"concepts":[{"id":"https://openalex.org/C39743133","wikidata":"https://www.wikidata.org/wiki/Q3262595","display_name":"Signalling","level":2,"score":0.5507000088691711},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5504999756813049},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.46059998869895935},{"id":"https://openalex.org/C3018449070","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signalling pathways","level":3,"score":0.4174000024795532},{"id":"https://openalex.org/C148043351","wikidata":"https://www.wikidata.org/wiki/Q4456944","display_name":"Current (fluid)","level":2,"score":0.3693999946117401},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.36169999837875366},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.3440000116825104},{"id":"https://openalex.org/C60644358","wikidata":"https://www.wikidata.org/wiki/Q128570","display_name":"Bioinformatics","level":1,"score":0.30799999833106995},{"id":"https://openalex.org/C70721500","wikidata":"https://www.wikidata.org/wiki/Q177005","display_name":"Computational biology","level":1,"score":0.2865000069141388},{"id":"https://openalex.org/C88498014","wikidata":"https://www.wikidata.org/wiki/Q14859918","display_name":"Hedgehog signaling pathway","level":3,"score":0.2777000069618225},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.2770000100135803},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.2750000059604645},{"id":"https://openalex.org/C2781197716","wikidata":"https://www.wikidata.org/wiki/Q864574","display_name":"Biomarker","level":2,"score":0.2583000063896179},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2565000057220459}],"mesh":[{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015398","descriptor_name":"Signal Transduction","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D064726","descriptor_name":"Triple Negative Breast Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D064726","descriptor_name":"Triple Negative Breast Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D064726","descriptor_name":"Triple Negative Breast Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.2174/0118715206402646251115102627","doi":"https://doi.org/10.2174/0118715206402646251115102627","is_oa":false,"landing_page_url":"https://doi.org/10.2174/0118715206402646251115102627","pdf_url":null,"source":{"id":"https://openalex.org/S159246083","display_name":"Anti-Cancer Agents in Medicinal Chemistry","issn_l":"1568-0118","issn":["1568-0118","1871-5206","1875-5968","1875-5992"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","jufo-1","ki-jl-1","medline","norway-1"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-Cancer Agents in Medicinal Chemistry","raw_type":"journal-article"},{"id":"pmid:41588901","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/41588901","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anti-cancer agents in medicinal chemistry","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.6580497026443481,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":1,"referenced_works":["https://openalex.org/W4285741464"],"related_works":[],"abstract_inverted_index":{"INTRODUCTION:":[0],"Triple":[1],"Negative":[2],"Breast":[3],"Cancer":[4],"(TNBC),":[5],"which":[6,39,112],"makes":[7],"up":[8],"15%":[9],"of":[10,24,33,68,193,205,214],"all":[11],"breast":[12,206],"cancers,":[13],"is":[14,28,52],"widely":[15],"acknowledged":[16],"as":[17,180,208,210],"the":[18,25,31,41,74,82,104,190,202,211],"most":[19],"aggressive":[20],"and":[21,37,46,66,76,89,109,121,130,148,156,183,197,219,245],"challenging":[22],"subtype":[23],"disease.":[26],"It":[27,51],"characterized":[29],"by":[30],"absence":[32],"HER2":[34],"receptors,":[35],"progesterone,":[36],"estrogen,":[38],"limits":[40],"options":[42],"for":[43,85,145,225,234],"targeted":[44],"treatment":[45,87,127,184],"mainly":[47],"affects":[48],"younger":[49],"women.":[50],"associated":[53],"with":[54,143],"a":[55],"poor":[56],"prognosis":[57],"due":[58],"to":[59],"its":[60],"rapid":[61],"progression,":[62],"high":[63],"recurrence":[64],"rates,":[65],"risk":[67],"metastasizing":[69],"into":[70,222],"vital":[71],"organs":[72],"like":[73],"brain":[75],"lungs.":[77],"These":[78],"clinical":[79,120],"challenges":[80],"underscore":[81],"urgent":[83],"need":[84],"personalized":[86],"plans":[88],"innovative":[90],"therapeutic":[91,114,212],"strategies.":[92,128],"METHODS:":[93],"Numerous":[94],"studies":[95],"have":[96,124,135,161],"identified":[97],"dysregulated":[98,216],"signaling":[99,217],"pathways":[100,218],"in":[101,119,141,165,200],"TNBC,":[102],"including":[103],"PI3K/AKT/mTOR,":[105],"JAK/STAT,":[106],"Wnt/\u03b2-catenin,":[107],"Notch,":[108],"MAPK/ERK":[110],"pathways,":[111],"offer":[113],"targets.":[115],"RESULTS:":[116],"Recent":[117],"developments":[118],"molecular":[122],"research":[123,238],"presented":[125],"potential":[126,213,223],"Pembrolizumab":[129],"other":[131,157],"immune":[132],"checkpoint":[133],"inhibitors":[134,196],"demonstrated":[136],"significant":[137],"benefits":[138],"when":[139],"used":[140],"conjunction":[142],"chemotherapy":[144],"both":[146],"early-stage":[147],"metastatic":[149],"TNBC.":[150],"In":[151],"advanced":[152],"patients,":[153,236],"sacituzumab,":[154],"govitecan,":[155],"Antibody-Drug":[158],"Conjugates":[159],"(ADCs)":[160],"shown":[162],"remarkable":[163],"efficacy":[164],"delivering":[166],"cytotoxic":[167],"medications,":[168],"improving":[169],"progression-free":[170],"survival.":[171],"Significant":[172],"obstacles":[173],"still":[174],"exist":[175],"despite":[176],"these":[177],"developments,":[178],"such":[179],"tumor":[181],"heterogeneity":[182],"resistance.":[185],"DISCUSSION:":[186],"This":[187],"review":[188],"highlights":[189],"beneficial":[191],"effects":[192],"small":[194],"molecule":[195],"combination":[198],"therapies":[199],"treating":[201],"deadliest":[203],"type":[204],"cancer,":[207],"well":[209],"targeting":[215],"providing":[220],"insight":[221],"avenues":[224],"developing":[226],"new":[227],"therapies.":[228],"CONCLUSION:":[229],"To":[230],"significantly":[231],"enhance":[232],"outcomes":[233],"TNBC":[235],"future":[237],"must":[239],"concentrate":[240],"on":[241],"identifying":[242],"predictive":[243],"biomarkers":[244],"refining":[246],"individualized":[247],"therapy":[248],"plans.":[249]},"counts_by_year":[{"year":2026,"cited_by_count":1}],"updated_date":"2026-09-26T08:19:03.415552","created_date":"2026-01-28T00:00:00"}